Methods for diagnosis and therapy of hematological and virus-associated malignancies
AssigneeCorixa Corporation
InventorsAlexander Gaiger, Martin A. Cheever, Susan Hand-Zimmermann
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.
Claims8
A method for inhibiting the development of a hematological malignancy in a patient, comprising administering to a patient an effective amount of a polypeptide comprising at least an immunogenic portion of Her2/neu, or a polynucleotide encoding said polypeptide, wherein said hematological malignancy is selected from the group consisting of AML, CML, CLL, MDS, myelomas, Hodgkin lymphomas and non-Hodgkin lymphomas, and thereby inhibiting the development of the hematological malignancy in the patient.
A method for inhibiting the development of a hematological malignancy in a patient, comprising administering to a patient an effective amount of antigen-presenting cells that express a polypeptide comprising at least an immunogenic portion of Her2/neu, wherein said hematological malignancy is selected from the group consisting of AML, CML, CLL, MDS, myelomas, Hodgkin lymphomas and non-Hodgkin lymphomas, and thereby inhibiting the development of the hematological malignancy in the patient.
A method for inhibiting the development of a hematological malignancy in a patient, comprising the steps of:
- (a) incubating CD4+ and/or CD8+T cells isolated from a patient with at least one component selected from the group consisting of:
- (i) a polypeptide comprising at least an immunogenic portion of Her2/neu;
- (ii) a polynucleotide encoding such a polypeptide;
- and
- (iii) an antigen-presenting cell that expresses such a polypeptide;
- such that T cells proliferate;
- and
- (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a hematological malignancy in the patient.
Dependencies are inferred from the claim text.